Phase 2 Depression and Anxiety Trial, Recruiting NCT06854224 Sponsor: Marianne Goodman Condition: Depression and Anxiety
Back to Depression And Anxiety

Phase 2 Depression and Anxiety Trial, Recruiting

NCT06854224
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are veterans of the military
  • People who are between 18 and 70 years of age
  • People who have a primary diagnosis of Major Depressive Disorder (a form of depression), confirmed by a study psychiatrist and a structured interview
  • People who have made a suicide attempt at some point in their life and are experiencing thoughts of suicide at the time of joining the study, as measured by a standard rating scale

Who may not be able to join:

  • People who have a significant medical or neurological (brain or nervous system) condition
  • People currently taking certain medications that affect how the body processes drugs — specifically strong CYP3A liver enzyme activators, moderate CYP3A inhibitors, or strong CYP3A inducers (confirm with trial site for specific medications)
  • People currently taking the heart medication digoxin
  • People who are currently pregnant, nursing, trying to become pregnant, or not using contraception
  • People with an active substance use disorder (such as alcohol or drug misuse) in the last six months, or who have or have had a psychotic disorder, bipolar disorder, or obsessive-compulsive disorder
  • People who have experienced a severe traumatic brain injury
  • People who are considered to be at immediate risk of acting on thoughts of suicide or of harming others
  • People with unstable medical conditions or any medical reason that would make taking the study medication (suvorexant) unsafe, as determined by the trial's medical team

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 718-584-9000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Marianne Goodman
Registry
ClinicalTrials.gov
Start date
1 September 2025
Est. completion
1 July 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Implicit Association Tests (IATs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov